Navigation Links
Study finds greater potential benefit in overall survival for eribulin compared with capecitabine
Date:6/12/2013

(Lebanon, NH, 6/11/13) Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits. Specifically, these analyses demonstrated a greater potential benefit in certain subsets of patients with metastatic breast cancer. This analysis was presented by Peter A. Kaufman, M.D., during the 2013 ASCO Annual Meeting.

The specific patient populations who appeared to benefit from eribulin, in comparison to capecitabine, are as follows:

  • Patients with more than two organs involved with metastatic breast cancer
  • Patients who had not received chemotherapy for six months or longer
  • Patients who had received anthracycline and/or a taxane therapies in the metastatic setting

Previous pre-specified exploratory analysis of overall survival and progression-free survival showed women with triple-negative, ER-negative, HER2-negative also had a greater relative benefit in overall survival with eribulin over capecitabine.

"These exploratory analyses suggest that other patient subgroups may benefit from eribulin and further studies are warranted," said Peter A. Kaufman, MD, associate professor of medicine at the Geisel School of Medicine at Dartmouth, and oncologist at Dartmouth-Hitchcock and Norris Cotton Cancer Center in Lebanon, N.H.

In 2010, the FDA approved eribulin for the treatment of patients with metastatic breast cancer who had previously received an anthracycline and a taxane and at least two cytotoxic chemotherapy treatment regimens for metastatic breast cancer. The FDA granted approval based on data showing a statistically significant improvement in overall survival compared with current treatments.

Kaufman and colleagues are still compiling data from the quality-of-life analysis, which according to Kaufman, will help guide their next steps in further studying eribulin in this patient population.


'/>"/>

Contact: Donna Dubuc
donna.m.dubuc@hitchcock.org
603-653-3615
Dartmouth-Hitchcock Medical Center
Source:Eurekalert

Related medicine news :

1. New Study Links Poor Sleep and Prostate Cancer
2. Researcher awarded grant to study food insecurity in homes of child with special healthcare needs
3. Study finds cancer guidelines do not fully meet IOM standards
4. Our Lady of Lourdes Medical Center & The Heart House Participating in Research Study Using Adult Stem Cells for Chronic Cardiac Condition
5. High Bit Security: 2/3 of All Data Breaches Preventable With Proactive Security Testing, New Ponemon Institute Study Documents Breach Causes and Costs
6. Alzheimer's Pilot Study Proposed for Ustekinumab (Stelara)
7. Capital Health Institute's Study Shows Migraine Headaches Prevalent Among Teen Girls
8. Workers do not quit due to mandatory flu shot, says Loyola study
9. Study finds obese mothers program their kids to be fat, but legacy can be overturned
10. Study shows cardiac MRI use reduces adverse events for patients with acute chest pain
11. Great HealthWorks, Makers of Omega XL, Report on New Omega-3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... Coalition Duchenne, a Newport Beach, California based charity committed ... in the April 25 U.S. Food and Drug Administration advisory committee hearing on ... the Marriott Conference Center in Hyattsville, Maryland was attended by over than a ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society for Assisted Reproductive ... are required to report in vitro fertilization (IVF) delivery rates to ... practice of assisted reproductive technologies in the United States. , This year, ...
(Date:4/29/2016)... ... 2016 , ... The number of chronically and seriously ill individuals is growing. ... an urgent need for highly skilled care managers and care coordinators. Care ... train and retain care managers, and enhance their skills. , Care Excellence ...
(Date:4/28/2016)... ... April 29, 2016 , ... Monthly subscription boxes are all the ... They recently reviewed the ZEN BOX , the aromatherapy subscription box. , ZEN ... oils (like lavender or frankincense) and one Zen Blend (like immune boost, sublime sleep ...
(Date:4/28/2016)... ... 2016 , ... Sanford Health’s work in cellular therapy and ... and leaders from Sanford Health were selected to participate in the “ Third ... and receive the 2016 Pontifical Key Innovation Award at the Vatican. , The ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... Transparency Market Research has published ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... skincare devices market was valued at US$ 7,255.8 Mn ... CAGR of 10.1% from 2015 to 2023 to reach ... full Skincare Devices Market (Treatment Device - LED Therapy Devices, ...
Breaking Medicine Technology: